POMDOCTOR LIMITED American Depositary Shares - Asset Resilience Ratio
POMDOCTOR LIMITED American Depositary Shares (POM) has an Asset Resilience Ratio of 0.53% as of March 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2018)
This chart shows how POMDOCTOR LIMITED American Depositary Shares's Asset Resilience Ratio has changed over time. See POM FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down POMDOCTOR LIMITED American Depositary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see POMDOCTOR LIMITED American Depositary Sh market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $656.00 Million | 0.53% |
| Total Liquid Assets | $656.00 Million | 0.53% |
Asset Resilience Insights
- Limited Liquidity: POMDOCTOR LIMITED American Depositary Shares maintains only 0.53% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
POMDOCTOR LIMITED American Depositary Shares Industry Peers by Asset Resilience Ratio
Compare POMDOCTOR LIMITED American Depositary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cachet Pharmaceutical Co Ltd
SHE:002462 |
Pharmaceutical Retailers | 0.00% |
|
d1000 Varejo Farma Participações S.A
SA:DMVF3 |
Pharmaceutical Retailers | 2.05% |
|
Raia Drogasil S.A
SA:RADL3 |
Pharmaceutical Retailers | 0.38% |
|
Empreendimentos Pague Menos S.A
SA:PGMN3 |
Pharmaceutical Retailers | 0.00% |
|
High Tide Inc
V:HITI |
Pharmaceutical Retailers | 0.03% |
|
Yifeng Pharmacy
SHG:603939 |
Pharmaceutical Retailers | 19.16% |
|
Sastasundar Ventures Limited
NSE:SASTASUNDR |
Pharmaceutical Retailers | 2.38% |
|
Yunnan Hongxiang Yixintang
SHE:002727 |
Pharmaceutical Retailers | 4.78% |
Annual Asset Resilience Ratio for POMDOCTOR LIMITED American Depositary Shares (2003–2018)
The table below shows the annual Asset Resilience Ratio data for POMDOCTOR LIMITED American Depositary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.67% | $804.00 Million | $119.67 Billion | -0.16pp |
| 2017-12-31 | 0.84% | $976.00 Million | $116.70 Billion | +0.04pp |
| 2016-12-31 | 0.80% | $917.00 Million | $114.90 Billion | +0.69pp |
| 2015-12-31 | 0.11% | $18.00 Million | $16.33 Billion | +0.09pp |
| 2014-12-31 | 0.02% | $3.00 Million | $15.67 Billion | +0.03pp |
| 2013-12-31 | -0.01% | $-1.00 Million | $14.85 Billion | -0.01pp |
| 2012-12-31 | 0.01% | $1.00 Million | $15.78 Billion | -0.03pp |
| 2011-12-31 | 0.03% | $5.00 Million | $14.91 Billion | -1.53pp |
| 2010-12-31 | 1.56% | $45.00 Million | $2.88 Billion | -7.22pp |
| 2009-12-31 | 8.78% | $1.39 Billion | $15.78 Billion | +0.68pp |
| 2008-12-31 | 8.10% | $1.33 Billion | $16.48 Billion | -1.06pp |
| 2007-12-31 | 9.16% | $1.38 Billion | $15.11 Billion | -0.12pp |
| 2006-12-31 | 9.27% | $1.32 Billion | $14.24 Billion | +0.02pp |
| 2005-12-31 | 9.25% | $1.30 Billion | $14.02 Billion | +0.13pp |
| 2004-12-31 | 9.12% | $1.22 Billion | $13.35 Billion | +8.92pp |
| 2003-12-31 | 0.21% | $28.00 Million | $13.43 Billion | -- |
About POMDOCTOR LIMITED American Depositary Shares
Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company's busines… Read more